Market Overview:
The global radioimmunotherapy market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, increasing demand for targeted therapies, and technological advancements in the field of radioimmunotherapy. Based on type, the global radioimmunotherapy market is segmented into non-Hodgkin lymphoma (NHL), follicular lymphoma, solid tumors, breast cancer, ovarian cancer, osteosarcoma, neuroblastoma and prostate cancer. Based on application, the market is segmented into tumor antigens and radionuclides. Geographically speaking North America dominates the global radioimmunotherapy market followed by Europe owing to better reimbursement scenario in these regions coupled with presence of key players operating in this space.
Product Definition:
Radioimmunotherapy is a cancer treatment that uses radiation therapy and monoclonal antibodies. The radiation therapy kills the cancer cells, and the monoclonal antibody helps deliver the radiation to the cancer cells. Radioimmunotherapy is used to treat many types of cancers, including lymphoma, leukemia, pancreatic cancer, and breast cancer.
Non Hodgkin Lymphoma (NHL):
Non-Hodgkin lymphoma (NHL) is a type of cancer that begins with the immune system.
Primary NHL, which occurs in the early stages of life; • Metastatic or advanced stage, which has spread to other organs (liver, lungs or bone);.
Follicular Lymphoma:
Follicular lymphoma is a type of cancer that occurs in the cells of the immune system known as B-lymphocytes. These are responsible for protecting the body from foreign particles such as bacteria and viruses. The abnormal growth of these cells into tumors causes symptoms such as swelling in one or more areas, especially near to the eyes, mouth, stomach or bowel; fatigue; loss of appetite; shortness of breath and others.
Application Insights:
Based on application, the global radioimmunotherapy market is segmented into tumor antigens, radionuclides, antibodies and others. Tumor antigens dominated the overall market in terms of revenue share in 2017 owing to an increase in the prevalence of cancer globally. Radioimmunotherapy uses antibody-targeting particles that recognize and bind to cancer cells only. Thus, it has been found effective for treating various types of cancers such as neuroblastoma, osteosarcoma and solid tumors among others.
Radionuclides are used for diagnosis as well as treatment purposes; however, their use is limited to specific applications due to safety concerns regarding their disposal after they have served their purpose. The growing usage of radiolabeled antibodies for targeted drug delivery has led authorities across the globe adopt regulations related thereto which would restrict its usage outside clinical trials without approval from a regulatory authority or Institutional Review Board (IRB).
Regional Analysis:
North America dominated the global radioimmunotherapy market in 2017. This can be attributed to the presence of major players, increased adoption of RIT for treatment, and high healthcare expenditure in this region. In addition, favorable reimbursement policies are also expected to drive growth during the forecast period. For instance, under Medicare Part B coverage is given for radiotherapy with either seeds or antibodies for cancer treatment based on tumor type and stage. Seeds-based radiotherapy is considered safer than antibody-based therapy as it results in fewer side effects such as allergic reactions and infections at the site where a radioactive implant was placed (1).
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing awareness about various types of cancer treatments available along with rising disposable income levels that enable people access better quality healthcare services (2). Moreover, growing investment by governments & private organizations coupled with supportive government policies will boost regional market development during the forecast period.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the radioimmunotherapy market. According to the American Cancer Society, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S., and approximately 595,690 people died from this disease. This number is expected to rise in the coming years due to increasing population and aging population.
- Rising demand for targeted therapies: The demand for targeted therapies is rising due to their better efficacy and fewer side effects as compared to traditional chemotherapy regimens. Radioimmunotherapy is a type of targeted therapy that uses monoclonal antibodies (mAbs) conjugated with radionuclides (radioisotopes) to specifically target tumor cells without affecting normal tissues nearby. This makes it an attractive treatment option for patients with various types of cancers including breast cancer, prostate cancer, colorectal cancer, etc.
- Technological advancements: Radioimmunotherapy technology has been evolving over time with continuous technological advancements such as development of novel mAbs and radioisotopes targeting different types of tumors cells with high specificity and affinity resulting in improved patient outcomes.. For instance,. In 2017,. AstraZeneca announced positive results from a Phase III study evaluating its investigational product brigatinib – an oral tyrosine kinase inhibitor – as first-line treatment for patients with advanced non-small cell lung carcinoma (NSCL
Scope Of The Report
Report Attributes
Report Details
Report Title
Radioimmunotherapy Market Research Report
By Type
Non Hodgkin Lymphoma (NHL), Follicular Lymphoma, Solid Tumors, Breast Cancer, Ovarian Cancer, Osteosarcoma, Neuroblastoma, Prostate Cancer
By Application
Tumor Antigens, Radionuclides, Antibodies
By Companies
Bayer Healthcare Pharmaceuticals, BioSynthema, Clarity Pharmaceuticals, Curasight, Endocyte, Immunomedics, Molecular Insight Pharmaceuticals, Nordic Nanovector, PDL Biopharma, Philogen, RadioMedix, Stella Pharma, Telix Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Radioimmunotherapy Market Report Segments:
The global Radioimmunotherapy market is segmented on the basis of:
Types
Non Hodgkin Lymphoma (NHL), Follicular Lymphoma, Solid Tumors, Breast Cancer, Ovarian Cancer, Osteosarcoma, Neuroblastoma, Prostate Cancer
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tumor Antigens, Radionuclides, Antibodies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer Healthcare Pharmaceuticals
- BioSynthema
- Clarity Pharmaceuticals
- Curasight
- Endocyte
- Immunomedics
- Molecular Insight Pharmaceuticals
- Nordic Nanovector
- PDL Biopharma
- Philogen
- RadioMedix
- Stella Pharma
- Telix Pharmaceuticals
Highlights of The Radioimmunotherapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Non Hodgkin Lymphoma (NHL)
- Follicular Lymphoma
- Solid Tumors
- Breast Cancer
- Ovarian Cancer
- Osteosarcoma
- Neuroblastoma
- Prostate Cancer
- By Application:
- Tumor Antigens
- Radionuclides
- Antibodies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Radioimmunotherapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Radioimmunotherapy is a type of cancer treatment that uses radio waves and antibodies to destroy cancer cells. The radio waves cause the antibodies to attack and kill the cancer cells.
Some of the major companies in the radioimmunotherapy market are Bayer Healthcare Pharmaceuticals, BioSynthema, Clarity Pharmaceuticals, Curasight, Endocyte, Immunomedics, Molecular Insight Pharmaceuticals, Nordic Nanovector, PDL Biopharma, Philogen, RadioMedix, Stella Pharma, Telix Pharmaceuticals.
The radioimmunotherapy market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Radioimmunotherapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Radioimmunotherapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Radioimmunotherapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Radioimmunotherapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Radioimmunotherapy Market Size & Forecast, 2020-2028
4.5.1 Radioimmunotherapy Market Size and Y-o-Y Growth
4.5.2 Radioimmunotherapy Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Non Hodgkin Lymphoma (NHL)
5.2.2 Follicular Lymphoma
5.2.3 Solid Tumors
5.2.4 Breast Cancer
5.2.5 Ovarian Cancer
5.2.6 Osteosarcoma
5.2.7 Neuroblastoma
5.2.8 Prostate Cancer
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Tumor Antigens
6.2.2 Radionuclides
6.2.3 Antibodies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Radioimmunotherapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Radioimmunotherapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Non Hodgkin Lymphoma (NHL)
9.6.2 Follicular Lymphoma
9.6.3 Solid Tumors
9.6.4 Breast Cancer
9.6.5 Ovarian Cancer
9.6.6 Osteosarcoma
9.6.7 Neuroblastoma
9.6.8 Prostate Cancer
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Tumor Antigens
9.10.2 Radionuclides
9.10.3 Antibodies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Non Hodgkin Lymphoma (NHL)
10.6.2 Follicular Lymphoma
10.6.3 Solid Tumors
10.6.4 Breast Cancer
10.6.5 Ovarian Cancer
10.6.6 Osteosarcoma
10.6.7 Neuroblastoma
10.6.8 Prostate Cancer
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Tumor Antigens
10.10.2 Radionuclides
10.10.3 Antibodies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Non Hodgkin Lymphoma (NHL)
11.6.2 Follicular Lymphoma
11.6.3 Solid Tumors
11.6.4 Breast Cancer
11.6.5 Ovarian Cancer
11.6.6 Osteosarcoma
11.6.7 Neuroblastoma
11.6.8 Prostate Cancer
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Tumor Antigens
11.10.2 Radionuclides
11.10.3 Antibodies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Non Hodgkin Lymphoma (NHL)
12.6.2 Follicular Lymphoma
12.6.3 Solid Tumors
12.6.4 Breast Cancer
12.6.5 Ovarian Cancer
12.6.6 Osteosarcoma
12.6.7 Neuroblastoma
12.6.8 Prostate Cancer
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Tumor Antigens
12.10.2 Radionuclides
12.10.3 Antibodies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Non Hodgkin Lymphoma (NHL)
13.6.2 Follicular Lymphoma
13.6.3 Solid Tumors
13.6.4 Breast Cancer
13.6.5 Ovarian Cancer
13.6.6 Osteosarcoma
13.6.7 Neuroblastoma
13.6.8 Prostate Cancer
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Tumor Antigens
13.10.2 Radionuclides
13.10.3 Antibodies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Radioimmunotherapy Market: Competitive Dashboard
14.2 Global Radioimmunotherapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer Healthcare Pharmaceuticals
14.3.2 BioSynthema
14.3.3 Clarity Pharmaceuticals
14.3.4 Curasight
14.3.5 Endocyte
14.3.6 Immunomedics
14.3.7 Molecular Insight Pharmaceuticals
14.3.8 Nordic Nanovector
14.3.9 PDL Biopharma
14.3.10 Philogen
14.3.11 RadioMedix
14.3.12 Stella Pharma
14.3.13 Telix Pharmaceuticals
